Search
Vadimezan
go.drugbank.com/drugs/DB06235InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnSitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor AntagonistsTemsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the E...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAVE9633
go.drugbank.com/drugs/DB06318InvestigationalAVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIndisulam
go.drugbank.com/drugs/DB06370InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve e...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDeramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. It antagonizes ...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors